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In human diabetic nephropathy, the extent of tubulointerstitial ﬁbrosis is the leading cause of end-stage renal disease; ﬁbrosis is
closely correlated with renal dysfunction. Although a wide array of medicinal plants play a role in the prevention and treatment
of diabetes, there are few reports of the application of herbal medicines in amelioration of renal ﬁbrosis, or the underlying
mechanisms by which such beneﬁts are mediated. The eﬃcacy of the Ayurvedic antidiabetic medicine Salacia oblonga (SO) root
on rat renal ﬁbrosis was investigated. An aqueous extract from SO (100 mg/kg, p.o., 6 weeks) diminished renal glomerulosclerosis
and interstitial ﬁbrosis in Zucker diabetic fatty (ZDF) rats, as revealed by van Giesen-staining. SO also reduced renal salt-soluble,
acid-soluble and salt-insoluble collagen contents. These changes were accompanied by normalization of hypoalbuminemia and
BUN. Gene proﬁling revealed that the increase in transcripts encoding the glomerulosclerotic mediators collagen I, collagen IV,
ﬁbronectin, angiotensin II type 1 receptor (AT1), transforming growth factor (TGF)-β1, plasminogen activator inhibitor (PAI)-
1 observed in ZDF rat kidney was suppressed by SO. In rat-derived mesangial cells, similar to the eﬀect of the AT1 antagonist
telmisartan, SO and its major component mangiferin suppressed the stimulatory eﬀect of angiotensin II on proliferation and
increased mRNA expression and/or activities of collagen I, collagen IV, ﬁbronectin, AT1, TGF-β1 and PAI-1. Considered together
the present ﬁndings demonstrate that SO attenuates diabetic renal ﬁbrosis, at least in part by suppressing anigiotensin II/AT1
signaling.Further, it now emerges that mangiferin is an eﬀective antiﬁbrogenic agent.
1.Introduction
Fibroproliferative diseases, including cardiovascular disease,
progressive kidney disease and macular degeneration, are
leading causes of morbidity and mortality and can aﬀect
all tissues and organ systems. Nevertheless, despite the
enormousimpactoftheseconditionsonhumanhealth,there
are currently no approved treatments that directly target the
mechanism(s) of ﬁbrosis [1]. Diabetic nephropathy is the
leading cause of end-stage renal disease worldwide and is
an independent risk factor for all-cause and cardiovascular
mortalities in diabetic patients. Diabetic nephropathy is
structurally characterized by an early thickening of tubular
and glomerular basement membranes due to the excessive
accumulationof the extracellular matrix [2]. Excessive depo-
sition of extracellular matrix in the glomerular mesangium
and tubulointerstitium is closely associated with a progres-
sive decline in renal function in diabetes [2, 3]. In human
diabetic nephropathy, the extent of glomerulosclerosis and
tubulointerstitial ﬁbrosis are well correlated with renal
dysfunction [4–6]. Accordingly, prevention and treatment of
renal ﬁbrosis may improve renal dysfunction.
It is well known that activation of the renin-angiotensin-
aldosterone system is critical for development of cardio-
vascular and renal ﬁbrosis in hypertension and diabetes.
Although all major components of the renin-angiotensin-
aldosterone system can exhibit proﬁbrotic activity, angio-
tensin II, the principal constituent peptide of the renin-
angiotensin-aldosterone system, plays an important role in
the development of renal ﬁbrosis [7]. Chronic angiotensin2 Evidence-Based Complementary and Alternative Medicine
II infusion induces extensive renal ﬁbrosis in rats [8]. The
angiotensin converting enzyme inhibitor enalapril inhibits
glomerular gene expression of extracellular matrix proteins
in diabetic rats [9]. In mesangial cell culture, angiotensin
II increases the synthesis of matrix proteins such as col-
lagen type I and ﬁbronectin; this can be inhibited by the
angiotensin II type 1 receptor (AT1) antagonist losartan
[10]. It has been suggested recently that targeting the renin-
angiotensin-aldosterone system might be an eﬀective strat-
egy to decrease ﬁbrogenesis in progressive renal disease [11].
Recently, there has been increased global interest in tra-
ditional medicines, including Ayurveda (traditional Indian)
and Chinese medicines [12–14]. Although these medicines
have been used for prevention and treatment of various
disordersforseveralthousandyears,moreextensivescientiﬁc
evaluation of their mechanisms of action and provision of a
strong evidence base are still required. Salacia species (e.g.,
S.oblonga, S. prinoides, S.reticulata), known as“Ponkoranti”
in Ayurvedic medicine, are widely distributed in Sri Lanka,
India, China, Vietnam, Malaysia, Indonesia and other coun-
tries. The roots and stems of these plants have been used
in the treatment of diabetes and obesity in the Ayurvedic
system of Indian traditional medicine [15, 16]. Mangiferin,
oneofthemaincomponentsinSalaciaspecies,isalsopresent
in relatively abundant amounts in some fruits (e.g., mango)
and other traditional anti-diabetic herbs and teas (e.g., Ane-
marrhenaasphodeloides, Mangifera indica, Aspalathuslinearis
and Cyclopia intermedia)[ 16, 17]. Recently, Salacia species
have been extensively consumed in Japan, USA and other
countries as food supplements for the prevention of obesity
and diabetes and they have been the subject of broad studies
for diabetes management. It has been demonstrated that
aqueousextractsoftherootofS.oblongaWall. (Celastraceae)
(SO) activate the peroxisome proliferator-activated receptor
(PPAR)-α [18], and ameliorate postprandial hyperglycemia,
hyperlipidemia, hepatic steatosis, cardiac lipid accumulation
and ﬁbrosis in Zucker diabetic fatty (ZDF) rats [18–21]. It
has not yet been evaluated whether this traditional antidia-
beticherbalmedicineisalsobeneﬁcialinrenalcomplications
associated with diabetes.
The aims of the present study were to examine the eﬀects
and underlying mechanism of SO and its major component
mangiferin on rat renal ﬁbrosis using ZDF rats and rat-
derived primary mesangial cells.
2.Methods
2.1. Chemicals and Reagents. Kits for determination of
collagen (Biocolor, Brisbane, Australia), albumin (BioAssay
Systems, Sydney, Australia), BUN (Sigma, Sydney, Australia)
and glucose (Wako, Osaka, Japan), and uric acid (Wako,
Osaka, Japan) and mangiferin (MA, Sigma, Sydney, Aus-
tralia) were purchased commercially.
2.2. Animals and Diet. Male Zucker lean (ZL) and ZDF
rats aged 13–15 weeks were obtained from Monash Uni-
versity Animal Services (Clayton, Victoria, Australia). Male
Sprague-Dawley rats weighing 130–150g were purchased
from the Experimental Animal Center, Sun Yat-Sen Univer-
sity (Guangzhou, China). The animals were housed in an
air-conditioned room at 23 ± 1◦Cw i t ha1 2 - hl i g h t / d a r k
cycle and were provided ad libitum with water and standard
pelleted diets. Animals were allowed free access to the food
and water. All animal experimental procedures were in
accordance with guidelines set by the National Health and
Medical Research Council of Australia, and approved by
the animal ethics committees of the University of Sydney,
Australia or Sun Yat-Sen University, China.
2.3. Preparation and Identiﬁcation of Aqueous SO Extract.
SO roots were collected from Tamil Nadu, India and their
identitywasconﬁrmedusingbotanicalandpharmacognostic
criteria. The voucher sample was deposited with the Phar-
mafood Institute (Kyoto, Japan; voucher No: PS0075). The
aqueous SO extract was prepared as previously described
[19]. The yield of the extract from the dried root was 6.5%.
SO extract was characterized by HPLC [21] and the content
of MA, a prominent component considered suitable for the
qualityassurance ofSalaciaspeciesanditsproducts[22],was
found to be 1.4%, which is within the previously reported
range (Japanese patent P2002-267655).
2.4. Treatment Protocol. Plasma glucose levels in non-fasted
animals were determined prior to any treatment. Animals
were then subdivided into experimental groups on the basis
of plasma glucose level and body weight: ZL control, ZL SO,
ZDF control and ZDF SO groups (ﬁve animals per group).
There were no diﬀerences in plasma glucose concentrations
or body weight between the two ZL groups or between the
two ZDF groups; these parameters were substantially lower
in ZL groups than in ZDF groups (data not shown), which
is consistent with the previous reports [18–21]. SO at a
dose of 100mg/kg, which was obtained from the previous
experiments [18–21], was suspended in 5% Gum Arabic
and administered to animals by oral gavage once daily for
6 weeks. The same volume of vehicle (5% Gum Arabic) was
administered to animals in the control group. The animals
were weighed once after 3-4 days in order to determine the
volumes of the test sample to be administered.
2.5. Measurement of Blood Biochemical Parameters and
Kidney Weight. Non-fasting blood samples (anti-coagulated
with heparin) were obtained from the tail veins of rats at the
age of 20–22 weeks using light halothane anesthesia. Plasma
samples were stored at −80◦C for subsequent determination
of albumin, BUN and uric acid (using the commercially
available kits, listed above). The animals were euthanized
by rapid dislocation of the neck vertebra. The kidneys were
rapidly excised and accurately weighed. A segment of the
right kidney was cut into slices, frozen in liquid nitrogen
and stored at −80◦C for collagen assay and gene expression
analysis.
2.6.Renal Histology and Determination ofRenal Fibrosis. The
remaining kidney segment was immediately ﬁxed in 10%
neutral formalin and prepared for pathological examina-
tion. Renal ﬁbrosis was measured essentially as describedEvidence-Based Complementary and Alternative Medicine 3
Table 1: Sequences of primers used in the ampliﬁcation of renal genes by RT-PCR
Gene Accession no.
or reference
Forward primer Reverse primer Size (bp) Temp. (◦C)
Collagen I Li et al. [27] 5 -CATAAAGGGTCATCGTGGCTTC-3  5 -GTGATAGGTGATGTTCTGGGAG-3  ∼500 62
Collagen IV Li et al. [27] 5 -GCAGGTGTGCGGTTTGTGAAG-3  5 -AGCTCCCCTGCCTTCAAGGTG-3  328 55
Fibronectin NM019143 5 -CAAGACCATACCTGCCGAAT-3  5 -CCGTGTAAGGGTCAAAGCAT-3  417 63
AT1 NM030985 5 -GAGAGGATTCGTGGCTTGAG-3  5 -TAAGTCAGCCAAGGCGAGAT-3  464 62
TGF-β1 NM021578 5 -GACCTGCTGGCAATAGCTTC-3  5 -GACTGGCGAGCCTTAGTTTG-3  468 58
PAI-1 M24067 5 -CCCTTCCAGAGTCCCATACA-3  5 -CAGGCGTGTCAGCTCATTTA-3  485 60
uPA NM013085 5 -CAGATCCGATGCTCTTAGCC-3  5 -GCTGCTCCACCTCAAACTTC-3  458 61
β-actin NM031144 5 -AGCCATGTACGTAGCCATCC-3  5 -CTCTCAGCTGTGGTGGTGAA-3  228 60
Temp, temperature.
previously [19, 23]. To determine the degree of collagen
ﬁber accumulation, forty ﬁelds in three individual sections
were randomly selected and the areas of van Giesen-stained
interstitial collagen deposit and the total kidney area were
determined by image analysis (KS 400 Imaging System;
Carl Zeiss Vision, Eching, Germany). The ratio of the
areas of interstitial collagen deposit to the total kidney
area was calculated. The glomerular cross-sectional areas
in hematoxylin-eosin (HE)-stained slices were determined
morphometrically. The cross-sectional area was measured in
glomeruli that were cut transversely. The outer borders of
the glomeruli were traced at 200× magniﬁcation, and the
glomerular areas were calculated. Fifty glomeruli per kidney
were counted, and the averaged value was used for analysis.
2.7. Renal Collagen Assay. The composition of collagen in
renal tissue was analyzed using the commercially available
Sircol Collagen Assay (Biocolor Ltd, Northern Ireland),
a colorimetric method in which Sirius red dye binds to
the side chains of amino acids found in collagen. The
salt soluble collagen and covalently cross-linked insoluble
collagen fractions were obtained by the successive treatment
of rat kidney with salt soluble collagen buﬀer (0.05M Tris
buﬀer, pH 7.5, 1.0 M NaCl), acetic acid (0.5M, pH 3.0)
and Milli-Q water (with heating to 80◦C, 1h). Aliquots of
extract (50μl) were mixed gently with 1ml of Sircol dye
reagent, incubated for 30min at room temperature, and
then centrifuged at 10000g to isolate the collagen-bound
dye in precipitated material. One milliliter of alkali reagent
was then added to release the collagen-bound dye into the
supernatant. After vortex-mixing (5min) and centrifugation
at 10000g (15min), 200μl of supernatant was transferred to
96-well plate, and the absorbance at 550nm was measured
in a micro-plate reader. The concentration was determined
from standard curves, and the collagen content in the kidney
tissue was expressed relative to the total dry weight.
2.8. Cell Culture. Primary cultures of rat mesangial cell
were prepared as previously described [24–26]. Brieﬂy,
rats were euthanased by prompt dislocation of the neck
vertebra. In order to prevent contamination with interstitial
ﬁbroblasts the bilateral kidney cortical tissues distant from
the medulla were harvested. The tissues were minced in
Hanks’ balanced salt solution. The suspension was ﬁltered
using 100, 200 and 250 mesh sieves and centrifuged twice
at 400g for 2min to obtain puriﬁed renal glomeruli. The
resultant cell pellets were dispersed and incubated in HBSS
containing 375U/ml collagenase type 1 (Gibco, China) at
37◦C for 15min. After recentrifugation the cell pellet was re-
suspended in a mixture of 80% RPMI 1640 medium (Gibco)
and 20% fetal bovine serum containing 100ng/ml insulin,
55 ng/ml transferrin, 50pg/ml selenium acid and antibiotics
(Gibco). The cells were incubated in an environment of 5%
CO2–95% O2 at 37◦C. Mesangial cells were identiﬁed by
morphological characterization and immunocytochemistry;
they stained positive for vimentin and α-smooth muscle
actin and negative for factor VIII and cytokeratinexpression.
Cells at passage 1–4 were used in all experiments.
2.9. Cell Viability and Proliferation. Cell viability was deter-
minedbyMTT assay.Inbrief,cells(1 ×104 cells)weregrown
to 70% conﬂuence in 48 cell culture wells and were then
serum-starved for ∼16–18h. The medium was replaced with
fresh medium containing various concentrations of SO (10,
20 and 40μg/ml), MA (25μM, Sigma, Guangzhou, China)
or telmisartan (10μM, Sigma) 1 h before treatment with
angiotensin II (10−6 M). After 20h, MTT stock solution
(5mg/ml; Sigma) was added and 4h later the media was
removed and cells were kept in 200μlo fD M S Of o r1 5m i n .
The optical density at 570nm was measured in a Gemini
Microplate reader.
DNA synthesis was assayed by 3H-thymidine incorpora-
tion. Conﬂuentmesangial cellsin 24-well culturedisheswere
serum-deprived for 16–18h. SO (10, 20 and 40μg/ml), MA
(25μM) or telmisartan (10μM) was added to the medium
with 10% FBS and 1μCi/ml 3H-thymidine (Beijing Atom
High-tech Co. Ltd, Beijing, China) 1h before treatment
with angiotensin II (10−6 M) and 24h later, the cells were
washed three times with cold PBS (Boster, AR0030, Wuhan,
China). DNA was precipitated at 4◦Cb yt r e a t m e n tw i t h5 %
trichloroacetic acid for 1h and the pellet was dissolved in
0.1M NaOH and absolute ethanol; radioactivity was deter-
mined by liquid scintillation counting (Beckman Counter,
LS6000, Minnesota, USA).4 Evidence-Based Complementary and Alternative Medicine
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Figure 1: Renal ﬁbrosis and kidney weights 6 weeks after treatment of male ZL and ZDF rats with vehicle (con) or SO extract. The renal
van Giesen-stained collagen deposit area andthe total renal tissuearea were determined by imageanalysis.(a)–(d)Representative samplesof
renal ﬁbrosis (red) (magniﬁcation 200×); (e) the ratio of the area of collagen accumulation to the total renal tissue area; (f) kidney weight.
All values are means ± SEM (n = 5, each group). ∗P<. 05.
2.10. ELISA Analysis of Fibronectin and Transforming Growth
Factor-β Protein Levels in Rat Mesangial Cells. Conﬂuent
rat primary mesangial cells in 6-well culture dishes were
serum-deprivedfor ∼16–18h. SO(10,20and 40μg/ml), MA
(25μM) or telmisartan (10μM) were added to the medium
in 10% FBS 1h prior to treatment with angiotensin II
(10−6 M).Twenty-four hourslater,themediumwascollected
for determination of ﬁbronectin and transforming growth
factor (TGF-β) protein levels by ELISA (Boster) according to
the manufacturer’s instructions.
2.11. Gene Expression Analysis in Rat Kidney and Rat-Derived
Mesangial Cells. Total RNA was prepared from the kidneys
of individual rats or rat mesangial cells using TRIzol reagent
(Invitrogen, Australia and Invitrogen, China). The relative
levels of speciﬁc mRNAs were determined by reverse tran-
scriptase polymerase chain reaction (RT-PCR), as described
previously [18, 20, 21]. Single-stranded cDNA was synthe-
sized from 1μg of total RNA using SuperScript II RNase H
Reverse Transcriptase, as per the manufacturer’s instructions
(Invitrogen, Australia and Invitrogen, China). PCR was
performed on a thermocycler (PTC-200 DNA engine, MJ
Research Inc, MA, USA). The genes examined were collagen
I, collagen IV, ﬁbronectin, plasminogen activator inhibitor
(PAI)-1, urokinase-type plasminogen activator (uPA),
TGF-β1 and AT1. The sequences of the sense and antisense
primers used for ampliﬁcation are shown in Table 1.
PCR samples were electrophoresed on 3% agarose gels
and stained with ethidium bromide. The gel images were
digitally captured with a CCD camera and analyzed using
ImageJ 1.29x software (NIH, USA). RT-PCR values are
presented as ratios of the speciﬁed gene signal in the selected
linear ampliﬁcation cycle relative to the signal for β-actin
(housekeeping gene).
2.12. Data Analysis. All results are expressed as means ±
SEM.Datawereanalyzedbysingle-factor analysis ofvariance
(ANOVA). If a statistically signiﬁcant eﬀect was found, the
Newman-Keuls test was performed to isolate the diﬀerence
between the groups. P-values < .05 were considered to
indicate signiﬁcance.
3.Results
3.1. Renal Histology and Collagen Accumulation in ZL and
ZDF Rats. SO has been demonstrated previously to ame-
liorate postprandial hyperglycemia, hyperlipidemia, hepatic
steatosis, cardiac lipid accumulation and ﬁbrosis in ZDF
rats [18–21]. In the present study, the extent of renal
ﬁbrosis in ZL and ZDF rats was ﬁrst assessed using the
van Giesen-staining method. Renal glomerulosclerosis andEvidence-Based Complementary and Alternative Medicine 5
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Figure 2: Renal tissue morphometry and glomerular cross-sectional areas 6 weeks after treatment with vehicle or SO extract in male ZL and
ZDF rats. The cross-sectional area was measured in glomeruli (hematoxylin-eosin staining). (a)–(d) Representative samples (magniﬁcation
200×); (e) glomerular cross-sectional areas. All values are means ± SEM (n = 5, each group). ∗P<. 05.
interstitial ﬁbrosis with tubular atrophy were evident in
sections from ZDF rats (Figure 1(c)). The stained area (red
color) was more extensive in the glomerular mesangium and
tubulointerstitium of ZDF rats (Figure 1(c)), compared with
ZL rats (Figure 1(a)). Thus, the area of collagen deposition
as a proportion of total kidney tissue was increased in ZDF
rats to 2-fold of ZL controls (P<. 05; Figure 1(e)). The
kidney weights of ZDF rats were increased by 15% over
those in ZL rats (P<. 05; Figure 1(f)). SO treatment over
a 6-week period signiﬁcantly diminished the extent of van
Gieson-staining by 40% in ZDF rats (P<. 05), but had
minimal eﬀect in ZL rats (Figures1(b), 1(d) and 1(e)). This
treatment did not aﬀect kidney weight in rats of either
genotype (Figure 1(f)).
Glomerular cross-sectional areas in ZDF rats were 1.5-
fold of those in ZL rats (P<. 05; Figures 2(a), 2(c) and 2(e)).
However, SO treatment minimally aﬀected the glomerular
cross-sectional area in kidney of ZL and ZDF rats (Figures
2(b), 2(d) and 2(e)).
Furthermore, the eﬀects of SO treatment on the nature
of the collagens present in rat kidneys were analyzed. It was
found that the quantities of total salt soluble (Figure 3(a)),
acid soluble (Figure 3(b)) and insoluble (Figure 3(c)) colla-
gens were elevated by 46, 22 and 72%, respectively, in the
kidneys of ZDF rats compared with ZL control (P<. 05).
Although treatment with SO signiﬁcantly decreased renal
total collagen contents in all animals, the eﬀects were more
pronounced in ZDF rats than in ZL rats.
3.2. Biochemical Parameters Relating to Renal Function in
ZL and ZDF Rats. Glomerular and interstitial injury and
ﬁbrosis may induce renal dysfunction. Consistent with
previousreports [27,28], ZDFrats were found in the present
study to exhibit elevated BUN (34% increase compared with
ZL control; P<. 05) and plasma uric acid levels (to 2-fold of
ZL control;P<. 05)aswell asdecreased serum albumin con-
centrations (to 75% of ZL control; P<. 05) (Figures 3(d)–
3(f)), which is due to prolonged urinary protein excretion.
Importantly, SO treatment restored albumin concentrations
to those found in ZL rat plasma and also normalized BUNin
ZDFrats(Figures3(d)and 3(e)).However,SOtreatment did
not aﬀect plasma uric acid (UA) concentrations in ZDF rats
(Figure 3(f)), or the corresponding parameters in ZL rats.
3.3. Cell Proliferation in Rat-Derived Mesangial Cells. The
eﬀect of SO, MA and the AT1 antagonist telmisartan
on angiotensin II-induced mesangial cell proliferation was
assessed. Cell viability, as reﬂected by MTT assay, and
proliferation, reﬂected by 3H-thymidine incorporation, were
signiﬁcantly increased (by 18 and 70%, resp.) after stimula-
tion with angiotensin II (Figures 4(a) and 4(b)). Treatment
with SO at concentrations of 20 and 40 μg/ml, as well as6 Evidence-Based Complementary and Alternative Medicine
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Figure 3: Composition of renal collagens and serum biochemical parameters reﬂecting renal function in rats. The composition of collagen
in kidney tissue was analyzed using the colorimetric Sircol Assay. The collagen content in the kidney tissue was standardized to the total dry
weight of renal tissue. The biochemical parameters were quantiﬁed enzymatically. Renal salt-soluble collagen (a), acid-soluble collagen (b),
insoluble collagen (c), plasma albumin (d), BUN, (e) and plasma uric acid (f). All values are means ± SEM (n = 5, each group). ∗P<. 05.
MA (25 μM) and telmisartan (10 μM), all suppressed the
angiotensin II-induced increase in cell viability (between 10
and 15%; all P<. 05) and proliferation (by 18–26%; all
P<. 05), whereas the low concentration of SO (10μg/ml)
showed minimal eﬀect.
3.4. Renal Gene Expression Proﬁles
3.4.1. Genes Implicated in Fibrogenesis. Deposition of extra-
cellular matrix proteins including collagen I, collagen IV
and ﬁbronectin is an important component of the scar-
ring observed during the evolution of glomerulosclerosis
and tubulointerstitial ﬁbrosis [29]. In the present study,
renal expression of these ﬁbrogenic genes was determined.
Consistent with increased renal ﬁbrosis, ZDF rats showed
increased renal expression of collagen I, collagen IV and
ﬁbronectin at the mRNA level (by 55, 32 and 32%, resp.)
compared with ZL-control (P<. 05; Figures 5(a)–5(c)). SO
treatment normalized the expression of all three genes when
administered to ZDF rats; interestingly, collagen I and IV
mRNAswere also decreased in ZL rats after SO treatment. In
culturedrat mesangial cells, SO (40μg/ml), MA (25μM) and
telmisartan (10μM)alleﬀectivelysuppressedtheangiotensin
II-stimulated induction of collagen I (by 16–40%; all P<
.05) and collagen IV (by 24–34%; P<. 05) expression
(Figures 6(a) and 6(b)). Similarly, ﬁbronectin expression at
the mRNA and protein levels were also normalized (Figures
6(c) and 6(d)).
3.4.2. AT1 and TGF-β1G e n e s .TGF-β is a key factor in
glomerulosclerosis and interstitial ﬁbrosis. The synthesis
and secretion of TGF-β1 are activated by angiotensin II
signaling through the AT1 [1] and leads in turn to enhance
TGF-β1 signaling. AT1 and TGF-β1m R N A sw e r eb o t h
upregulated by 22 and 72%, respectively, in kidneys of ZDF
rats; these increases were attenuated by SO treatment to
levels comparable with those in ZL control rats (Figures 7(a)
and 7(b)). In accord with these in vivo ﬁndings, angiotensin
II treatment of mesangial cells also signiﬁcantly upregulated
AT1 mRNA expression by 27% (Figure 7(c))a n dT G F - β1
mRNA and protein expression by 55 and 62% over control,
respectively (Figures 7(d) and 7(e)). Treatment of cells
with SO (40μg/ml), MA (25μM) and telmisartan (10μM)
reversed these eﬀects on AT1 and TGF-β1 and protein level
in mesangial cells (Figures 7(c)–7(e)).Evidence-Based Complementary and Alternative Medicine 7
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Figure 4:AngiotensinII-induced cell proliferationin rat-derived mesangialcells.SO(SO10:10;SO20:20 andSO40:40μg/ml),MA(25μM)
or telmisartan (Tel, 10μM) was added 1h before mesangial cells were treated with angiotensin II (10−6 M). Cell viability was determined by
MTT assay((a),n = 6, each group) and DNA synthesis was assessed by 3H-thymidine incorporation((b), n = 6, each group), as described in
“Methods” section. All values are means ± SEM. ∗P<. 05.
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Figure 5: Renal expression of collagen (Col) I (a), Col IV (b), ﬁbronectin (c) mRNAs in ZL and ZDF rats. Total RNA was extracted from
renal tissues using TRIzol. The relative levels of speciﬁc mRNAs were determined by RT-PCR. Results were normalized to β-actin. All values
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Figure 6: Expression of collagen (Col) I (a), Col IV (b), ﬁbronectin (c) mRNAs and ﬁbronectin protein (d) in rat mesangial cells. SO
(SO10: 10; SO20: 20 and SO40: 40μg/ml), MA (25μM) or telmisartan (Tel. 10μM) was added 1h before mesangial cells were treated with
angiotensin II (10−6 M). Twenty-four hours later total RNA was extracted from the mesangial cells using TRIzol. The relative levels of
speciﬁc mRNAs were determined by RT-PCR. Results were normalized to β-actin. In a parallel experiment, the medium was collected after
mesangial cells were treated with the test agents in combination with angiotensin II. ﬁbronectin protein was determined by commercial
ELISA kit according to the manufacturer’s instructions. All values are means ± SEM (n = 3, each group). ∗P<. 05.
3.4.3. Genes Implicated in Fibrinolysis. PAI-1 is the principal
inhibitor of plasminogen activation [30]a n du P Ai sa
central activator of ﬁbrinolysis. As part of the present study,
the renal expression of these genes that participate in the
synthesis and degradation of the extracellular matrix was
examined. Renal PAI-1 mRNA was upregulated signiﬁcantly
by43%inZDFrats(Figure 8(a)),althoughrenal uPAmRNA
expression was unchanged (Figure 8(b)), the ratio of renal
uPA to PAI-1 mRNAs was decreased by 29% (P<. 05;
Figure 8(c)). SO treatment of ZDF rats and, to a lesser
extent, ZL rats signiﬁcantly decreased PAI-1 mRNA by 46
and 15%, respectively, but was without eﬀect on uPA mRNA
expression. Thus, there was a corresponding increase in
the uPA:PAI-1 ratio in SO-treated animals that was more
pronounced in ZDF rats (88% increase) than in ZL rats
(18% increase) (both P<. 05; Figure 8(c)). Findings in
mesangial cells were consistent with in vivo ﬁndings. Similar
to telmisartan (10μM) (decreased by 36.7%, P<. 05),
SO (40μg/ml) and MA (25μM) signiﬁcantly suppressed
the angiotensin II-mediated increase in PAI-1 mRNA (P<
.05; Figure 8(d)) and prevented the angiotensin II-induced
decline in uPA mRNA expression (P<. 05; Figure 8(e))a n d
the uPA : PAI-1 mRNA ratio (Figure 8(f)).
4.Discussion
The present study clearly demonstrates that SO treatment
attenuates the renal interstitial ﬁbrosis, glomerulosclerosis
and collagen deposition in ZDF rats, as revealed by van
Giesen-staining. Consistently, the elevated renal expres-
sion of ﬁbrogenic genes including collagen I, collagen
I Va n dﬁ b r o n e c t i ni nZ D Fr a t s ,w a sr e s t i t u t e db yS O
treatment. Moreover, SO treatment ameliorated the increase
in both insoluble and soluble collagens in the kidneysEvidence-Based Complementary and Alternative Medicine 9
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Figure 7:RenalexpressionofAT1(a)andTGF-β1 (b) inZL andZDFrats,andlevels ofAT1 (c)andTGF-β1 (d) mRNAs, and TGF-β protein
(e)inratmesangialcells.In cellculture, SO(SO10:10;SO20:20andSO40:40μg/ml),MA(25μM)ortelmisartan(Tel.10μM)wasadded 1h
prior to treatment with angiotensinII (10−6 M), followed by twenty-four hours incubation. Total RNA was extracted from renal tissues and
the mesangial cells using TRIzol, respectively. The relative levels of speciﬁc mRNAs were determined by RT–PCR. Results were normalized
to β-actin. In a parallel experiment, the medium was collected after mesangial cells were treated with the test agents in combination with
angiotensin II. TGF-β protein level was determined by commercial ELISA kit according to the manufacturer’s instructions. All values are
means ± SEM (n = 5, each group in vivo; n = 3, each group in vitro). ∗P<. 05.
of ZDF rats. These improvements were accompanied by
the normalization of BUN and hypoalbuminemia, ﬁnd-
ings that are consistent with the attenuation of diabetic
nephropathy.
Angiotensin II is a renal growth factor, inducing hyper-
plasia and hypertrophy in a cell type-dependent fashion.
A n g i o t e n s i nI Ii sak e yf a c t o ri nt h ei n ﬂ a m m a t o r ya n d
ﬁbrotic response in kidney diseases [31]. This vasoactive
peptide activates mesangial and tubular cells and interstitial
ﬁbroblasts, increasing the expression and synthesis of extra-
cellular matrix proteins, such as collagen I and ﬁbronectin
[7, 10, 32, 33]; these eﬀects are mediated by angiotensin II
via the AT1 [10].
Glucose has been shown to increase the production of
angiotensin II, thereby decreasing collagenase activity and
increasing collagendeposition;thelattereﬀectwasprevented
in rat mesangial cells by the AT1 antagonist losartan [34]. In
ZDF rats, AT1 mRNA and protein expression was increased
along with the associated glomerulopathy, upregulation of
the extracellular matrix protein ﬁbronectin, renal inﬂam-
mation and proteinuria; again, these eﬀects were attenuated
by losartan [28]. Thus, angiotensin II signaling is stimulated
in this animal model and leads to renal dysfunction and
ﬁbrogenesis. The present study demonstrated that the
overexpression of the AT1 gene in ZDF rat kidney was
normalized by SO treatment. Furthermore, SO and its
major constituent MA suppressed a range of angiotensin
II-induced cellular endpoints including hyperproliferation,
overexpression of collagen I, collagen IV and ﬁbronectin
mRNAs, and increased ﬁbronectin protein level in isolated
rat mesangial cells. Angiotensin II-dependent induction of
AT1 gene expression was also suppressed. These eﬀects were
similar to those elicited by the AT1 antagonist telmisartan.
Thus, the present ﬁndings assert that SO modulates10 Evidence-Based Complementary and Alternative Medicine
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Figure 8: Renal expression of PAI-1 (a), uPA (b) mRNAs, and the ratio of uPA to PAI-1 (c) in ZL and ZDF rats, and levels of PAI-1 (d) and
uPA (e) mRNAs, and the ratio of uPA to PAI-1 (f) in rat mesangial cells. In cell culture, SO (SO10: 10 and SO40: 40μg/ml), MA (25μM)
or Tel (10μM) was added 1 h prior to treatment with angiotensin II (10−6 M), followed by 24-h incubation. Total RNA was extracted from
renal tissues and the mesangial cells using TRIzol, respectively. The relative levels of speciﬁc mRNAs were determined by RT–PCR. Results
were normalized to β-actin. All values are means ± SEM (n = 5, each group in vivo; n = 3, each group in vitro). ∗P<. 05.
angiotensin II/AT1 signaling, which in turn attenuates cell
proliferation and ﬁbrogenesis in ZDF rat kidney, and that
MA is a candidate active constituent present in SO extracts.
TGF-β is a key factor in glomerulosclerosis and inter-
stitial ﬁbrosis that acts directly, by stimulating synthesis of
extracellular matrix components and reducing collagenase
production, and indirectly through other proﬁbrogenic fac-
t o r s .F u r t h e r m o r e ,T G F - β is important for the proliferation
of intrarenal ﬁbroblasts and the epithelial-mesenchymal
transition through which tubular cells become ﬁbroblasts
[35]. Numerous studies have demonstrated that TGF-β plays
a pivotal role in experimental diabetic kidney disease and
human diabetic nephropathy [32]. Angiotensin II stimulates
TGF-β expression in the kidney by several mechanisms
and upregulates receptors for TGF-β [35]. Apart from its
eﬀects on TGF-β1 secretion and activation, angiotensin
II also directly enhances TGF-β1 signaling [1]. Glucose-
induced TGF-β1 secretion was suppressed by losartan in rat
mesangial cells [34]. Thus, angiotensin converting enzyme
inhibitors and AT1 antagonists are two classes of drugs that
have the potential to inhibit angiotensin II-mediated TGF-β
expression [35]. In the present study, SO treatment reversed
t h ei n c r e a s ei nr e n a lT G F - β1 expression in ZDF rat kidney.
Moreover, similar to telmisartan, both SO and MA inhibited
the increase in TGF-β secretion and angiotensin II-induced
TGF-β1 gene expression in rat mesangial cells.
TGF-β1 activates the plasmin system by stimulating PAI-
1 gene expression [30]. PAI-1 has a number of important
roles in pathological processes, including the inhibition of
ﬁbrinolysis, regulation of extracellular matrix turnover and
activation of proenzymes and latent growth factors that
promote tissue ﬁbrosis and sclerosis [36]. In progressive
renal diseases, such as diabetic nephropathy, PAI-1 has been
identiﬁed as a critical mediator of glomerulosclerosis and
interstitial ﬁbrosis [36, 37]. The altered uPA to PAI-1 ratio
reﬂects a change from a proﬁbrinolytic to an antiﬁbrinolyticEvidence-Based Complementary and Alternative Medicine 11
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Figure 9: Proposed model showing SO- and MA-dependent
eﬀects on the angiotensin II/AT1 signaling pathway and ﬁbrogenic
mediators in diabetic rat kidneys.
state [38]. The shift toward the uPA-enriched proﬁbrinolytic
state favors renal collagen degradation. The present ﬁnding
that the increase in PAI-1 gene expression in ZDF rat kidney
was suppressed by SO treatment is consistent with the SO-
mediated decrease in renal collagen contents. In mesangial
cells, SO, MA and telmisartan treatment not only suppressed
angiotensin II-induced overexpression of PAI-1, but also
restituted uPA gene expression that had been suppressed by
angiotensin II; thus, the mRNA ratio of uPA to PAI-1 was
normalized. These ﬁndings were consistent with analogous
measurements in ZDF rats.
Becauseglucosestimulatestheproductionofangiotensin
II [34], it is conceivable that the reported improvement of
hyperglycemia by SO treatment [19] may also contribute to
the attenuation of renal ﬁbrosis in ZDF rats by decreasing
renal angiotensin II. However, it is also pertinent that
recent studies have provided compelling evidence that other
components of the renin-angiotensin-aldosterone system,
includingangiotensinIII,renin,andaldosteronealsoactivate
the TGF-β system [35]. It is now important to investigate
whether other mechanisms apart from the angiotensin
II/AT1 signaling pathway may also contribute to the antiﬁ-
brogenic activity of SO and its active constituent MA. In
this regard it is noteworthy that the SO extract also contains
other active components, such as salacinol, kotalanol and
kotalagenin 16-acetate [17]. The potential contributions of
these constituents to the biological actions of SO could be
considered in future studies.
5.Conclusion
The present ﬁndings demonstrate for the ﬁrst time that a tra-
ditionalantidiabeticherbalmedicineattenuatesrenalﬁbrosis
in ZDF rats, at least in part, by suppressing angiotensin
II/AT1 signaling, possibly as proposed in Figure 9.F u r t h e r -
more, it now emerges that MA is a candidate antiﬁbrogenic
agent.These studiesprovide new insights into the potentially
important renoprotective eﬀects and the underlying molec-
ular mechanism of action of SO.
Funding
Pharmafood Institute, Kyoto, Japan.
References
[1] T. A. Wynn, “Common and unique mechanisms regulate
ﬁbrosis in various ﬁbroproliferative diseases,” The Journal of
Clinical Investigation, vol. 117, no. 3, pp. 524–529, 2007.
[ 2 ]R .E .G i l b e r ta n dM .E .C o o p e r ,“ T h et u b u l o i n t e r s t i t i u mi n
progressive diabetic kidney disease: more than an aftermath
of glomerular injury?” Kidney International,v o l .5 6 ,n o .5 ,p p .
1627–1637, 1999.
[3] M. W. Steﬀes, R. Osterby, B. Chavers, and M. Mauer, “Mesa-
ngialexpansionas a central mechanism forlossof kidneyfun-
ction in diabetic patients,” Diabetes, vol. 38, pp. 1077–1081,
1984.
[ 4 ]R .B a d e r ,H .B a d e r ,K .E .G r u n d ,S .M a c k e n s e n - H a e n ,H .
Christ, and A. Bohle, “Structure and function of the kidney
in diabetic glomerulosclerosis. Correlations between mor-
phological and functional parameters,” Pathology, Research &
Practice, vol. 167, pp. 204–216, 1980.
[ 5 ]P .H .L a n e ,M .W .S t e ﬀe s ,P .F i o r e t t o ,a n dS .M .M a u e r ,“ R e n a l
interstitial expansion in insulin-dependent diabetes mellitus,”
Kidney International, vol. 43, no. 3, pp. 661–667, 1993.
[6] J. L. Taft, C. J. Nolan, S. P. Yeung, T. D. Hewitson, and F. I.
R. Martin, “Clinical and histological correlations of decline in
renal function in diabetic patients with proteinuria,” Diabetes,
vol. 43, no. 8, pp. 1046–1051, 1994.
[7] S. A. Mezzano, M. Ruiz-Ortega, and J. Egido, “Angiotensin II
and renal ﬁbrosis,” Hypertension, vol. 38, no. 3, pp. 635–638,
2001.
[8] W. Zhao, S. S. Chen, Y. Chen, R. A. Ahokas, and Y. Sun, “Kid-
neyﬁbrosisinhypertensiverats:roleofoxidativestress,”Amer-
ican Journal of Nephrology, vol. 28, no. 4, pp. 548–554, 2008.
[9] T. Nakamura, T. Takahasi, M. Fukui et al., “Enalapril atten-
uates increased gene expression of extracellular matrix
components in diabetic rats,” Journal of the American Society
of Nephrology, vol. 5, pp. 1492–1497, 1995.
[10] P. E. Ray, L. A. Bruggeman, S. Horikoshi, G. Aguilera, and P.
E. Klotman, “Angiotensin II stimulates human fetal mesangial
cell proliferation and ﬁbronectin biosynthesis by binding
to AT1 receptors,” Kidney International,v o l .4 5 ,n o .1 ,p p .
177–184, 1994.
[11] M.IwanoandE.G.Neilson,“Mechanismsoftubulointerstitial
ﬁbrosis,” Current Opinion in Nephrology and Hypertension,
vol. 13, no. 3, pp. 279–284, 2004.
[12] B. Patwardhan, D. Warude, P. Pushpangadan, and N. Bhatt,
“Ayurveda and traditional Chinese medicine: a comparative
overview,” Evidence-Based Complementary and Alternative
Medicine, vol. 2, no. 4, pp. 465–473, 2005.12 Evidence-Based Complementary and Alternative Medicine
[13] E. L. Cooper, “Ayurveda is embraced by eCAM,” Evidence-
Based Complementary and Alternative Medicine,v o l .5 ,n o .1 ,
pp. 1–2, 2008.
[14] E. L. Cooper, “Ayurveda and eCAM: a closer connection,”
Evidence-Based Complementary and Alternative Medicine,v o l .
5, no. 2, pp. 121–122, 2008.
[15] J. P. C. Chandrasena, in The Chemistry and Pharmacology of
Ceylon and Indian Medicinal Plants, H&C Press, Colombo, Sri
Lanka,1935.
[16] Y.Li,T.H.-W.Huang,andJ.Yamahara,“Salaciaroot,aunique
Ayurvedic medicine, meets multiple targets in diabetes and
obesity,” Life Sciences,vol. 82, no. 21-22, pp. 1045–1049, 2008.
[17] D. L. McKay and J. B. Blumberg, “A review of the bioactivity
ofSouthAfricanherbal teas:rooibos(Aspalathuslinearis)and
honeybush (Cyclopia intermedia),” Phytotherapy Research,
vol. 21, no. 1, pp. 1–16, 2007.
[18] T. H.-W. Huang, G. Peng, G. Q. Li, J. Yamahara, B. D.
Roufogalis, and Y. Li, “Salacia oblonga root improves
postprandial hyperlipidemia and hepatic steatosis in Zucker
diabetic fatty rats: activation of PPAR-α,” Toxicology and
Applied Pharmacology, vol. 210, no. 3, pp. 225–235, 2006.
[19] Y. Li, G. Peng, Q. Li et al., “Salacia oblonga improves cardiac
ﬁbrosis and inhibits postprandial hyperglycemia in obese
zuckerrats,”Life Sciences,vol.75,no.14,pp. 1735–1746,2004.
[20] T. H. Huang, Q. Yang, M. Harada et al., “Salacia oblonga
root improves cardiac lipid metabolism in Zucker diabetic
fatty rats: modulation of cardiac PPAR-alpha-mediated
transcription of fatty acid metabolic genes,” Toxicology and
Applied Pharmacology, vol. 210, pp. 78–85, 2006.
[21] TH Huang, L He, Q Qin et al.,“Salacia oblonga root decreases
cardiac hypertrophy in Zuckerdiabetic fattyrats:inhibition of
cardiac expression of angiotensinII type 1 receptor,” Diabetes,
Obesity and Metabolism, vol. 10, pp. 574–585, 2008.
[22] M. Yoshikawa, N. Nishida, H. Shimoda, M. Takada, Y. Kaw-
ahara,and H. Matsuda,“Polyphenolconstituents from salacia
species: quantitative analysisofmangiferinwith α-glucosidase
and aldose reductase inhibitory activities,” Yaku- gaku Zasshi,
vol. 121, no. 5, pp. 371–378, 2001.
[ 2 3 ]Y .L i ,I .K i s h i m o t o ,Y .S a i t oe ta l . ,“ G u a n y l y lc y c l a s e - Ai n -
hibits angiotensin II type 1A receptor-mediated cardiac remo-
deling, an endogenous protection mechanism in the heart,”
Circulation, vol. 106, pp. 1722–1728, 2002.
[24] R. Singh, N. Alavi, A. K. Singh, and D. J. Leehey, “Role of
angiotensin II in glucose-induced inhibition of mesangial
matrix degradation,” Diabetes, vol. 48, no. 10, pp. 2066–2073,
1999.
[ 2 5 ]R .F .C h o u i n a r d ,R .L .M e e k ,S .K .C o o n e y ,a n dK .R .
Tuttle, “Eﬀects of amino acids and glucose on mesangial cell
aminopeptidase a and angiotensin receptors,” Kidney Inter-
national, vol. 61, no. 1, pp. S106–S109, 2002.
[26] T. Tsuchiya, H. Shimizu, K. Shimomura, and M. Mori,
“Troglitazone inhibits isolated cell proliferation, and induces
apoptosis in isolated rat mesangial cells,” American Journal of
Nephrology, vol. 23, no. 4, pp. 222–228, 2003.
[27] Y. Li, Y. Qi, M. S. Kim et al., “Increased renal collagen cross-
linking and lipid accumulation in nephropathy of Zucker
diabetic fattyrats,”Diabetes/MetabolismResearch andReviews,
vol. 24, no. 6, pp. 498–506, 2008.
[28] Z.-G. Xu, L. Lanting, N. D. Vaziri et al., “Upregulation of
angiotensin II type 1 receptor, inﬂammatory mediators, and
enzymes of arachidonate metabolism in obese zucker rat
kidney: reversal by angiotensin II type 1 receptor blockade,”
Circulation, vol. 111, no. 15, pp. 1962–1969, 2005.
[29] G.Remuzzi,A.Benigni,andA.Remuzzi,“Mechanismsofpro-
gression and regression of renal lesions of chronic nephro-
pathies and diabetes,” The Journal of Clinical Investigation,v o l .
116, no. 2, pp. 288–296, 2006.
[ 3 0 ]L .R .L u n d ,A .R i c c i o ,P .A .A n d r e a s e ne ta l . ,“ T r a n s f o r m i n g
growth factor-beta is a strong and fast acting positive
regulator of the level of type-1 plasminogen-activator in-
hibitor messenger-RNAinWi-38 human lung ﬁbroblasts,” The
EMBO Journal, vol. 6, pp. 1281–1286, 1987.
[31] M. Ruiz-Ortega, M. Rup´ erez, V. Esteban et al., “Angiotensin
II: a key factor in the inﬂammatory and ﬁbrotic response in
kidney diseases,” Nephrology Dialysis Transplantation, vol. 21,
pp. 16–20, 2006.
[32] G. Wolf, U. Haberstroh, and E. G. Nielson, “Angiotensin II
stimulates the proliferation and biosynthesisof type I collagen
in cultured murine mesangial cells,” American Journal of
Pathology, vol. 140, pp. 95–107, 1992.
[33] S. Kagami, W. A. Border, D. E. Miller, and N. A. Noble,
“Angiotensin II stimulated extracellular matrix protein
synthesis through induction of transforming growth factor-b
expression in rat glomerular cells,” The Journal of Clinical
Investigation, vol. 93, pp. 2431–2437, 1994.
[34] R. Singh, N. Alavi, A. K. Singh, and D. J. Leehey, “Role of
angiotensin II in glucose-induced inhibition of mesangial
matrix degradation,” Diabetes, vol. 48, no. 10, pp. 2066–2073,
1999.
[35] G. Wolf, “Renal injury due to renin-angiotensin-aldosterone
system activation of the transforming growth factor-β
pathway,” Kidney International, vol. 70,no. 11, pp. 1914–1919,
2006.
[36] A. A. Eddy, “Plasminogen activator inhibitor-1 and the
kidney,” American Journal of Physiology, vol. 283, no. 2, pp.
F209–F220, 2002.
[ 3 7 ]A .B .F o g o ,“ R e n a lﬁ b r o s i s :n o tj u s tP A I - 1i nt h es k y , ”The
Journal of Clinical Investigation, vol. 112, pp. 326–328, 2003.
[ 3 8 ]K .B .D e a t r i c k ,J .L .E l i a s o n ,E .M .L y n c h ,A .J .M o o r e ,N .A .
Dewyer, M. R. Varma et al., “Vein wall remodeling after deep
vein thrombosis involves matrix metalloproteinases and late
ﬁbrosis in a mouse model,” Journal of Vascular Surgery,v o l .
42, pp. 140–148, 2005.